Hemolytic uremic syndrome: pathogenesis and update of interventions

The typical form of hemolytic uremic syndrome (HUS) is the major complication of Shiga toxin-producing Escherichia coli infections. HUS is a critical health problem in Argentina since it is the main cause of acute renal failure in children and the second cause of chronic renal failure, accounting fo...

Descripción completa

Detalles Bibliográficos
Autores: Palermo, Marina Sandra, Exeni, Ramón Alfonso, Fernández, Gabriela Cristina
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2009
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/55090
Acceso en línea:http://hdl.handle.net/11336/55090
Access Level:acceso abierto
Palabra clave:Escherichia Coli Infections
Hus
Fluid Therapy
Hemolitic Uremic Syndrome
Shiga Toxin
Argentina
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
id AR_193ffe88ef1b3ece37226a3da6418dfd
oai_identifier_str oai:ri.conicet.gov.ar:11336/55090
network_acronym_str AR
network_name_str Argentina
repository_id_str
spelling Hemolytic uremic syndrome: pathogenesis and update of interventionsPalermo, Marina SandraExeni, Ramón AlfonsoFernández, Gabriela CristinaEscherichia Coli InfectionsHusFluid TherapyHemolitic Uremic SyndromeShiga ToxinArgentinahttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The typical form of hemolytic uremic syndrome (HUS) is the major complication of Shiga toxin-producing Escherichia coli infections. HUS is a critical health problem in Argentina since it is the main cause of acute renal failure in children and the second cause of chronic renal failure, accounting for 20% of renal transplants in children and adolescents in Argentina. Despite extensive research in the field, the mainstay of treatment for patients with HUS is supportive therapy, and there are no specific therapies preventing or ameliorating the disease course. In this review, we present the current knowledge about pathogenic mechanisms and discuss traditional and innovative therapeutic approaches, with special focus in Argentinean contribution. The hope that a better understanding of transmission dynamics and pathogenesis of this disease will produce better therapies to prevent the acute mortality and the long-term morbidity of HUS is the driving force for intensified research.Fil: Palermo, Marina Sandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Exeni, Ramón Alfonso. Municipio de La Matanza. Hospital del Niño; ArgentinaFil: Fernández, Gabriela Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFuture Drugs Ltd.2009-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/55090Palermo, Marina Sandra; Exeni, Ramón Alfonso; Fernández, Gabriela Cristina; Hemolytic uremic syndrome: pathogenesis and update of interventions; Future Drugs Ltd.; Expert review of anti-infective therapy; 7; 6; 12-2009; 697-7071478-72101744-8336CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.1586/eri.09.49info:eu-repo/semantics/altIdentifier/doi/10.1586/eri.09.49info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2024-05-08T13:49:43Zoai:ri.conicet.gov.ar:11336/55090instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982024-05-08 13:49:43.643CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Hemolytic uremic syndrome: pathogenesis and update of interventions
title Hemolytic uremic syndrome: pathogenesis and update of interventions
spellingShingle Hemolytic uremic syndrome: pathogenesis and update of interventions
Palermo, Marina Sandra
Escherichia Coli Infections
Hus
Fluid Therapy
Hemolitic Uremic Syndrome
Shiga Toxin
Argentina
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
title_short Hemolytic uremic syndrome: pathogenesis and update of interventions
title_full Hemolytic uremic syndrome: pathogenesis and update of interventions
title_fullStr Hemolytic uremic syndrome: pathogenesis and update of interventions
title_full_unstemmed Hemolytic uremic syndrome: pathogenesis and update of interventions
title_sort Hemolytic uremic syndrome: pathogenesis and update of interventions
dc.creator.none.fl_str_mv Palermo, Marina Sandra
Exeni, Ramón Alfonso
Fernández, Gabriela Cristina
author Palermo, Marina Sandra
author_facet Palermo, Marina Sandra
Exeni, Ramón Alfonso
Fernández, Gabriela Cristina
author_role author
author2 Exeni, Ramón Alfonso
Fernández, Gabriela Cristina
author2_role author
author
dc.subject.none.fl_str_mv Escherichia Coli Infections
Hus
Fluid Therapy
Hemolitic Uremic Syndrome
Shiga Toxin
Argentina
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
topic Escherichia Coli Infections
Hus
Fluid Therapy
Hemolitic Uremic Syndrome
Shiga Toxin
Argentina
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
description The typical form of hemolytic uremic syndrome (HUS) is the major complication of Shiga toxin-producing Escherichia coli infections. HUS is a critical health problem in Argentina since it is the main cause of acute renal failure in children and the second cause of chronic renal failure, accounting for 20% of renal transplants in children and adolescents in Argentina. Despite extensive research in the field, the mainstay of treatment for patients with HUS is supportive therapy, and there are no specific therapies preventing or ameliorating the disease course. In this review, we present the current knowledge about pathogenic mechanisms and discuss traditional and innovative therapeutic approaches, with special focus in Argentinean contribution. The hope that a better understanding of transmission dynamics and pathogenesis of this disease will produce better therapies to prevent the acute mortality and the long-term morbidity of HUS is the driving force for intensified research.
publishDate 2009
dc.date.none.fl_str_mv 2009-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/55090
Palermo, Marina Sandra; Exeni, Ramón Alfonso; Fernández, Gabriela Cristina; Hemolytic uremic syndrome: pathogenesis and update of interventions; Future Drugs Ltd.; Expert review of anti-infective therapy; 7; 6; 12-2009; 697-707
1478-7210
1744-8336
CONICET Digital
CONICET
url http://hdl.handle.net/11336/55090
identifier_str_mv Palermo, Marina Sandra; Exeni, Ramón Alfonso; Fernández, Gabriela Cristina; Hemolytic uremic syndrome: pathogenesis and update of interventions; Future Drugs Ltd.; Expert review of anti-infective therapy; 7; 6; 12-2009; 697-707
1478-7210
1744-8336
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.1586/eri.09.49
info:eu-repo/semantics/altIdentifier/doi/10.1586/eri.09.49
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Future Drugs Ltd.
publisher.none.fl_str_mv Future Drugs Ltd.
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1799195346401755136
score 15,811543

Similares en LA Referencia